Free Trial
NASDAQ:ESPR

Esperion Therapeutics (ESPR) Stock Price, News & Analysis

Esperion Therapeutics logo
$1.12 -0.02 (-1.33%)
As of 12:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Esperion Therapeutics Stock (NASDAQ:ESPR)

Key Stats

Today's Range
$1.10
$1.16
50-Day Range
$0.73
$1.24
52-Week Range
$0.69
$3.94
Volume
1.18 million shs
Average Volume
4.56 million shs
Market Capitalization
$220.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Moderate Buy

Company Overview

Esperion Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

ESPR MarketRank™: 

Esperion Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 226th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Esperion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Esperion Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Esperion Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.29) to ($0.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Esperion Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Esperion Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Esperion Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    12.35% of the float of Esperion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Esperion Therapeutics has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in Esperion Therapeutics has recently decreased by 0.33%, indicating that investor sentiment is improving.
  • Dividend Yield

    Esperion Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Esperion Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.35% of the float of Esperion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Esperion Therapeutics has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in Esperion Therapeutics has recently decreased by 0.33%, indicating that investor sentiment is improving.
  • News Sentiment

    Esperion Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Esperion Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    7 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,706.00 in company stock.

  • Percentage Held by Insiders

    Only 1.70% of the stock of Esperion Therapeutics is held by insiders.

  • Percentage Held by Institutions

    47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Esperion Therapeutics' insider trading history.
Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Stock News Headlines

Research Analysts Offer Predictions for ESPR FY2027 Earnings
Central Banks Are Hoarding Gold – Should You?
The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and ushering in more economic uncertainty. Claim your FREE AI & Gold Report today and learn what central banks, investors, and analysts are seeing—and how gold can help protect your savings in an uncertain, AI-driven world.
Esperion Appoints Craig Thompson to Board of Directors
See More Headlines

ESPR Stock Analysis - Frequently Asked Questions

Esperion Therapeutics' stock was trading at $2.20 at the start of the year. Since then, ESPR shares have decreased by 48.6% and is now trading at $1.13.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) issued its earnings results on Tuesday, May, 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.03. The biopharmaceutical company earned $65 million during the quarter, compared to analysts' expectations of $54.97 million. Esperion Therapeutics had a negative trailing twelve-month return on equity of 0.91% and a negative net margin of 59.03%.
Read the conference call transcript
.

Top institutional shareholders of Esperion Therapeutics include UMB Bank n.a. (0.09%), Parallel Advisors LLC (0.06%), Sivia Capital Partners LLC (0.01%) and North Star Investment Management Corp. (0.01%). Insiders that own company stock include Benjamin Halladay, Benjamin Looker, Sheldon L Koenig, Eric Warren, Joanne M Foody and J Martin Carroll.
View institutional ownership trends
.

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/06/2025
Today
7/16/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ESPR
CIK
1434868
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

High Price Target
$16.00
Low Price Target
$3.00
Potential Upside/Downside
+519.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.74 million
Net Margins
-59.03%
Pretax Margin
-59.03%
Return on Equity
-0.91%
Return on Assets
-29.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.18
Quick Ratio
0.81

Sales & Book Value

Annual Sales
$332.31 million
Price / Sales
0.67
Cash Flow
$0.02 per share
Price / Cash Flow
49.11
Book Value
($1.97) per share
Price / Book
-0.57

Miscellaneous

Outstanding Shares
198,200,000
Free Float
194,830,000
Market Cap
$223.97 million
Optionable
Optionable
Beta
0.70

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ESPR) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners